PRLD
Prelude Therapeutics Inc

1,137
Mkt Cap
$124.93M
Volume
160,902.00
52W High
$4.22
52W Low
$0.6101
PE Ratio
-1.01
PRLD Fundamentals
Price
$1.63
Prev Close
$1.65
Open
$1.65
50D MA
$1.54
Beta
1.76
Avg. Volume
3.9M
EPS (Annual)
-$1.68
P/B
1.58
Rev/Employee
$53,435.11
Loading...
Loading...
News
all
press releases
Beat the Market the Zacks Way: Goldman Sachs, Micron, Prelude in Focus
GS stands out as Zacks showcases how its stock picks like MU and PRLD delivered strong gains despite a shaky market.
Zacks·18d ago
News Placeholder
More News
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...
PR Newswire·22d ago
News Placeholder
Prelude Therapeutics (NASDAQ:PRLD) Issues Earnings Results
Prelude Therapeutics (NASDAQ:PRLD - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.26) earnings per share for the quarter, topping the consensus...
MarketBeat·29d ago
News Placeholder
Prelude Therapeutics Inc Q3 Loss Decreases, Beats Estimates
(RTTNews) - Prelude Therapeutics Inc (PRLD) revealed Loss for third quarter that decreased from the same period last year and beat the Street estimates...
Nasdaq News: Markets·30d ago
News Placeholder
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prelude Therapeutics Incorporated (Prelude or the Company...
Business Wire·1mo ago

Latest PRLD News

View

Advertisement|Remove ads.

Advertisement|Remove ads.